Vemurafenib: Targeted Inhibition of Mutated BRAF for Treatment of Advanced Melanoma and Its Potential in Other Malignancies

Author： Sharma Anant   Shah Sachin R.   Illum Henrik   Dowell Jonathan  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.17, 2012-12, pp. : 2207-2222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies

By Gibney Geoffrey T  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 7, 2013-07 ,pp. : 893-899

Informa Healthcare

Access to resources Recommend Favorite

Vemurafenib for the treatment of melanoma

By Jordan Emmet John   Kelly Catherine M  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 17, 2012-12 ,pp. : 2533-2543

Informa Healthcare

Access to resources Recommend Favorite

Drug safety evaluation of vemurafenib in the treatment of melanoma

By Tsai Kenneth Y   Nowroozi Sasan   Kim Kevin B  

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 767-775

Informa Healthcare

Access to resources Recommend Favorite

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

By Ascierto Paolo A.   Margolin Kim  

Cancer, Vol. 120, Iss. 11, 2014-06 ,pp. : 1617-1619

Blackwell Publishing

Access to resources Recommend Favorite

Vemurafenib: Development of resistance during treatment for malignant melanoma: case report

By  

Reactions Weekly, Vol. 1, Iss. 1373, 2011-01 ,pp. : 30-31

Adis International

Access to resources Recommend Favorite